12th May 2006 07:00
ReGen Therapeutics PLC12 May 2006 12 May 2006 ReGen Therapeutics Plc places £820,000 of shares ReGen Therapeutics Plc ("ReGen" or the "Company") announces that it has placedthrough its brokers J M Finn & Co with new and existing shareholders 82,000,000new ordinary shares at 1p per share to raise £820,000, before expenses("Placing") Application will be made for 77,500,000 of these new ordinary shares to beadmitted to the AIM Market of the London Stock Exchange Plc and dealings areexpected to commence at 8am on 25 May 2006. Application will be made for thebalance of 4,500,000 new ordinary shares to be admitted to the AIM Market of theLondon Stock Exchange Plc and dealings are expected to commence at 8am on 8 June2006. Subsequent to the above Placing, the new enlarged share capital of the Companywill be 583,304,442 ordinary shares (the "Enlarged Share Capital"). Mr Peter Garrod, a Director of ReGen, is subscribing for 2,500,000 new ordinaryshares in the Placing making his total holding 63,750,000 representing 10.93% ofthe Enlarged Share Capital. Executive Chairman Percy Lomax commented, "The capital raised will be used tofund the proposed Phase IIa trials of zolpidem and development of Colostrinin(TM) for marketing". All new ordinary shares will rank pari passu with the existing ordinary shares of 0.1p each in the Company. For further information, please contact: Andrew MarshallGreycoat CommunicationsTel. 020 7960 6007Mobile: 07785 297111 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
TILS.L